VolitionRX Ltd (VNRX) - NYSEMKT
  • Jan. 7, 2015, 11:44 AM
    • Thinly-traded nano cap VolitionRx (OTCQB:VNRX +21.5%) jumps on a 6x surge in volume albeit on turnover of only 39K shares. This morning, the company announced the results from a blinded clinical study that showed its NuQ diagnostic platform detected 84% of early stage surgically-treatable pancreatic cancers with 92% specificity.
    • The NuQ system identifies and measures circulating nucleosomes in the blood. It can potentially differentiate between cancer types and other conditions such as endometriosis and inflammatory diseases.
    | Jan. 7, 2015, 11:44 AM
Company Description
VolitionRX Ltd. operates clinical-stage life sciences company, which focuses on developing blood-based diagnostic tests that meet the need for accurate, fast, inexpensive and scalable tests for detecting and diagnosing cancer and other diseases. The company was founded on August 5, 2010 and is... More
Sector: Healthcare
Industry: Diagnostic Substances
Country: Singapore